Sökning: onr:"swepub:oai:lup.lub.lu.se:ffec299a-f80f-4af6-9a59-121343a8b9b9" > High-Dose Chemother...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06947naa a2200829 4500 | |
001 | oai:lup.lub.lu.se:ffec299a-f80f-4af6-9a59-121343a8b9b9 | |
003 | SwePub | |
008 | 191217s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/ffec299a-f80f-4af6-9a59-121343a8b9b92 URI |
024 | 7 | a https://doi.org/10.1200/JCO.19.009152 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Dirksen, Utau University Hospital Essen4 aut |
245 | 1 0 | a High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases : Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 |
264 | 1 | c 2019 |
300 | a 11 s. | |
520 | a PURPOSE: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng |
700 | 1 | a Brennan, Bernadetteu Royal Manchester Children's Hospital4 aut |
700 | 1 | a Le Deley, Marie Cécileu University of Paris-Saclay,Centre Oscar Lambret4 aut |
700 | 1 | a Cozic, Nathalieu Institut Gustave Roussy4 aut |
700 | 1 | a van den Berg, Henku Emma Children’s Hospital,Academic Medical Center of University of Amsterdam (AMC)4 aut |
700 | 1 | a Bhadri, Viveku Cancer Institute of New South Wales4 aut |
700 | 1 | a Brichard, Bénédicteu Saint-Luc University Hospital4 aut |
700 | 1 | a Claude, Lineu Centre Léon Bérard4 aut |
700 | 1 | a Craft, Alanu University of Newcastle upon Tyne4 aut |
700 | 1 | a Amler, Susanneu Friedrich Loeffler Institute,University of Münster4 aut |
700 | 1 | a Gaspar, Natalieu Institut Gustave Roussy4 aut |
700 | 1 | a Gelderblom, Hansu Leiden University Medical Centre4 aut |
700 | 1 | a Goldsby, Robertu University of California, San Francisco,UCSF Benioff Children‘s Hospital4 aut |
700 | 1 | a Gorlick, Richardu University of Texas4 aut |
700 | 1 | a Grier, Holcombe E.u Boston Children's Hospital4 aut |
700 | 1 | a Guinbretiere, Jean Marcu Hôpital René-Huguenin4 aut |
700 | 1 | a Hauser, Peteru Semmelweis University4 aut |
700 | 1 | a Hjorth, Larsu Lund University,Lunds universitet,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Late effects after childhood cancer treatment,Lund University Research Groups4 aut0 (Swepub:lu)pedi-lhj |
700 | 1 | a Janeway, Katherineu Boston Children's Hospital4 aut |
700 | 1 | a Juergens, Heribertu University Hospital Münster4 aut |
700 | 1 | a Judson, Ianu Royal Marsden NHS Foundation Trust4 aut |
700 | 1 | a Krailo, Marku University of Southern California4 aut |
700 | 1 | a Kruseova, Jarmilau Charles University in Prague4 aut |
700 | 1 | a Kuehne, Thomasu University Children's Hospital, Basel4 aut |
700 | 1 | a Ladenstein, Ruthu Medical University of Vienna4 aut |
700 | 1 | a Lervat, Cyrilu Centre Oscar Lambret4 aut |
700 | 1 | a Lessnick, Stephen L.u Ohio State University4 aut |
700 | 1 | a Lewis, Ianu University of Leeds4 aut |
700 | 1 | a Linassier, Claudeu University Hospital of Tours4 aut |
700 | 1 | a Marec-Berard, Perrineu Pediatric Hematology and Oncology Institute (IHOPE)4 aut |
700 | 1 | a Marina, Neyssau Five Prime Therapeutics Inc4 aut |
700 | 1 | a Morland, Bruceu Birmingham Children's Hospital4 aut |
700 | 1 | a Pacquement, Hélèneu Curie Institute, Paris4 aut |
700 | 1 | a Paulussen, Michaelu Witten/Herdecke University4 aut |
700 | 1 | a Randall, R. Loru University of California, Davis4 aut |
700 | 1 | a Ranft, Andreasu Institut Gustave Roussy,University of Paris-Saclay4 aut |
700 | 1 | a Le Teuff, Gwénaëlu University of Birmingham4 aut |
700 | 1 | a Wheatley, Keithu University College London Hospital4 aut |
700 | 1 | a Whelan, Jeremyu The Children's Hospital of Philadelphia,University of Pennsylvania4 aut |
700 | 1 | a Womer, Richardu Seattle Children’s Hospital4 aut |
700 | 1 | a Oberlin, Odileu Institut Gustave Roussy4 aut |
700 | 1 | a Hawkins, Douglas S.u Children's Hospital and Regional Medical Center, Seattle,Seattle Children’s Hospital4 aut |
710 | 2 | a University Hospital Essenb Royal Manchester Children's Hospital4 org |
710 | 2 | a Euro-E.W.I.N.G. 99 Investigators |
710 | 2 | a Ewing 2008 Investigators |
773 | 0 | t Journal of Clinical Oncologyg 37:34, s. 3192-3202q 37:34<3192-3202x 0732-183X |
856 | 4 | u http://dx.doi.org/10.1200/JCO.19.00915y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/ffec299a-f80f-4af6-9a59-121343a8b9b9 |
856 | 4 8 | u https://doi.org/10.1200/JCO.19.00915 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy